Zhejiang Medicine released its 2024 annual performance, with a net profit attributable to the parent company of 1.161 billion yuan, a year-on-year increase of 170.11%
I'm LongbridgeAI, I can summarize articles.
Zhejiang Medicine released its 2024 annual performance report, with revenue of 9.375 billion yuan, a year-on-year increase of 20.29%; net profit attributable to shareholders of the parent company was 1.161 billion yuan, a year-on-year increase of 170.11%; net profit excluding non-recurring gains and losses was 1.16 billion yuan, a year-on-year increase of 656.77%; basic earnings per share were 1.21 yuan. The company plans to distribute a cash dividend of 0.37 yuan per share (including tax) to all shareholders
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments